teprotumumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
human origin	5387	1036734-93-6

Description:

Molecule

Description

Synonyms:

teprotumumab
teprotumumab-trbw
tepezza
RO4858696-000
R 1507
RG 1507

Teprotumumab-trbw’s mechanism of action in patients with Thyroid Eye Disease has not been fully characterized. Teprotumumab-trbw binds to IGF-1R and blocks its activation and signaling

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Jan. 21, 2020	FDA	HORIZON THERAPEUTICS IRELAND

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Muscle spasms	163.60	56.54	63	690	156087	63332182
Hypoacusis	101.11	56.54	28	725	24123	63464146
Amenorrhoea	98.82	56.54	23	730	9891	63478378
Tinnitus	57.82	56.54	20	733	35608	63452661
Blood glucose increased	57.02	56.54	25	728	83731	63404538

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Muscle spasms	112.87	55.20	42	471	174688	79569187

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L04AA53	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Selective immunosuppressants
FDA EPC	N0000193926	Insulin-like Growth Factor-1 Receptor Inhibitor
FDA MoA	N0000193927	Insulin-like Growth Factor-1 Receptor Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Thyroid eye disease	indication	276177000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Insulin-like growth factor 1 receptor	Kinase	P08069	IGF1R_HUMAN	ANTAGONIST	IC50	9		SCIENTIFIC LITERATURE	DRUG LABEL

External reference:

ID	Source
Y64GQ0KC0A	UNII
C2987429	UMLSCUI
CHEMBL1743079	ChEMBL_ID
DB06343	DRUGBANK_ID
9107	INN_ID
C558734	MESH_SUPPLEMENTAL_RECORD_UI
D09680	KEGG_DRUG
10612	IUPHAR_LIGAND_ID
018259	NDDF
840364008	SNOMEDCT_US
840397009	SNOMEDCT_US
4039110	VANDF
4039111	VANDF
5376617	PUBCHEM_CID
2274802	RXNORM
329754	MMSL
37968	MMSL
d09494	MMSL
C551399	MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
TEPEZZA	HUMAN PRESCRIPTION DRUG LABEL	1	75987-130	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAVENOUS	BLA	30 sections
TEPEZZA	HUMAN PRESCRIPTION DRUG LABEL	1	75987-130	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	500 mg	INTRAVENOUS	BLA	30 sections